2019 AHA科学声明:无阻塞性冠状动脉疾病心肌梗死患者的诊断和管理

2019-03-27 美国心脏协会 Circulation. 2019 Mar 27:CIR0000000000000670.

在所有接受冠状动脉动脉造影检查的急性心肌梗死患者中,无阻塞性冠状动脉疾病的心肌梗死约占5%-6%。本文主要提供了关于无阻塞性冠状动脉疾病心肌梗死(MINOCA)的最新定义,并针对患者的诊断、评估和管理提供了临床应用框架。

中文标题:

2019 AHA科学声明:无阻塞性冠状动脉疾病心肌梗死患者的诊断和管理

英文标题:

Contemporary Diagnosis and Management of Patients With Myocardial Infarction in the Absence of Obstructive Coronary Artery Disease: A Scientific Statement From the American Heart Association.

发布机构:

美国心脏协会

发布日期:

2019-03-27

简要介绍:

在所有接受冠状动脉动脉造影检查的急性心肌梗死患者中,无阻塞性冠状动脉疾病的心肌梗死约占5%-6%。本文主要提供了关于无阻塞性冠状动脉疾病心肌梗死(MINOCA)的最新定义,并针对患者的诊断、评估和管理提供了临床应用框架。 

拓展指南:心肌梗死相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=2019 AHA科学声明:无阻塞性冠状动脉疾病心肌梗死患者的诊断和管理)] GetToolGuiderByIdResponse(projectId=1, id=2565f1c001e25002, title=2019 AHA科学声明:无阻塞性冠状动脉疾病心肌梗死患者的诊断和管理, enTitle=Contemporary Diagnosis and Management of Patients With Myocardial Infarction in the Absence of Obstructive Coronary Artery Disease: A Scientific Statement From the American Heart Association., guiderFrom=Circulation. 2019 Mar 27:CIR0000000000000670., authorId=null, author=, summary=在所有接受冠状动脉动脉造影检查的急性心肌梗死患者中,无阻塞性冠状动脉疾病的心肌梗死约占5%-6%。本文主要提供了关于无阻塞性冠状动脉疾病心肌梗死(MINOCA)的最新定义,并针对患者的诊断、评估和管理提供了临床应用框架。 , cover=, journalId=null, articlesId=null, associationId=60, associationName=美国心脏协会, associationIntro=美国心脏协会(AHA,American Heart Association)是心脏病学领域比较正要的学会之一,致力于心脏病和卒中的预防与治疗,提供相关继续教育、流行病学年度报告。每年举办学术年会报道中的的临床试验结果等,有官方杂志《美国心脏协会杂志》,提供心血管疾病和卒中相关的指南及专家共识,更新的比较快。, copyright=0, guiderPublishedTime=Wed Mar 27 00:00:00 CST 2019, originalUrl=, linkOutUrl=, content=<div>在所有接受冠状动脉动脉造影检查的急性心肌梗死患者中,无阻塞性冠状动脉疾病的心肌梗死约占5%-6%。本文主要提供了关于无阻塞性冠状动脉疾病心肌梗死(MINOCA)的最新定义,并针对患者的诊断、评估和管理提供了临床应用框架。 </div> <div><br> </div> 拓展指南:<strong>与<font color=red>心肌梗死</font>相关指南:</strong><br><ul><li><a href="https://www.medsci.cn/guideline/show_article.do?id=6e5f21c001e059fe" title="2019 CCS/CAIC指南:ST段抬高型心肌梗死的紧急管理" target=_blank>2019 CCS/CAIC指南:ST段抬高型心肌梗死的紧急管理</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=295531c001e023b7" title="急性ST段抬高型心肌梗死溶栓治疗的合理用药指南(第2版)" target=_blank>急性ST段抬高型心肌梗死溶栓治疗的合理用药指南(第2版)</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=a0e5d1c00168612c" title="第四次心肌梗死全球统一定义(2018)要点解读:重视心肌损伤,细化心肌梗死诊断" target=_blank>第四次心肌梗死全球统一定义(2018)要点解读:重视心肌损伤,细化心肌梗死诊断</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=308dc1c00163255b" title="2018 第四版心肌梗死通用定义" target=_blank>2018 第四版心肌梗死通用定义</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=5cc351c00158a352" title="ST段抬高型急性心肌梗死院前溶栓治疗中国专家共识" target=_blank>ST段抬高型急性心肌梗死院前溶栓治疗中国专家共识</a></li> 更多信息请点击:<a href="https://www.medsci.cn/guideline/list.do?q=%E5%BF%83%E8%82%8C%E6%A2%97%E6%AD%BB" target=_blank>有关心肌梗死更多指南</a></ul>, tagList=[TagDto(tagId=88837, tagName=无阻塞性冠状动脉疾病), TagDto(tagId=334, tagName=心肌梗死)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=其他, guiderLanguage=0, guiderRegion=0, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5637, appHits=400, showAppHits=11, pcHits=3632, showPcHits=2283, likes=162, shares=10, comments=4, approvalStatus=1, publishedTime=Mon Apr 15 23:25:06 CST 2019, publishedTimeString=2019-03-27, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Mon Apr 15 23:25:06 CST 2019, updatedBy=null, updatedName=null, updatedTime=Thu Jan 04 20:16:15 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2019 AHA科学声明:无阻塞性冠状动脉疾病心肌梗死患者的诊断和管理)])
2019 AHA科学声明:无阻塞性冠状动脉疾病心肌梗死患者的诊断和管理
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1200054, encodeId=738a120005433, content=谢啦, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ee36505980, createdName=ms9000001125727904, createdTime=Sun Mar 06 22:03:46 CST 2022, time=2022-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=958212, encodeId=0fd9958212a7, content=谢啦, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc965444032, createdName=ms8000001588598650, createdTime=Mon Apr 19 07:20:51 CST 2021, time=2021-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364960, encodeId=270e364960dc, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2622354286, createdName=122b9cbbm13暂无昵称, createdTime=Sat Apr 20 12:34:23 CST 2019, time=2019-04-20, status=1, ipAttribution=)]
    2022-03-06 ms9000001125727904

    谢啦

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1200054, encodeId=738a120005433, content=谢啦, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ee36505980, createdName=ms9000001125727904, createdTime=Sun Mar 06 22:03:46 CST 2022, time=2022-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=958212, encodeId=0fd9958212a7, content=谢啦, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc965444032, createdName=ms8000001588598650, createdTime=Mon Apr 19 07:20:51 CST 2021, time=2021-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364960, encodeId=270e364960dc, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2622354286, createdName=122b9cbbm13暂无昵称, createdTime=Sat Apr 20 12:34:23 CST 2019, time=2019-04-20, status=1, ipAttribution=)]
    2021-04-19 ms8000001588598650

    谢啦

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1200054, encodeId=738a120005433, content=谢啦, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ee36505980, createdName=ms9000001125727904, createdTime=Sun Mar 06 22:03:46 CST 2022, time=2022-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=958212, encodeId=0fd9958212a7, content=谢啦, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc965444032, createdName=ms8000001588598650, createdTime=Mon Apr 19 07:20:51 CST 2021, time=2021-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364960, encodeId=270e364960dc, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2622354286, createdName=122b9cbbm13暂无昵称, createdTime=Sat Apr 20 12:34:23 CST 2019, time=2019-04-20, status=1, ipAttribution=)]
    2019-04-20 122b9cbbm13暂无昵称

    谢谢

    0